LakeShore Biopharma (LSB) AI Stock Analysis

• Market Cap: $20.42M
• Dividend Yield: N/A
• Average Volume (3M): 24.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 758
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,080,751
• 10 Day Avg. Volume: 18,655
• 30 Day Avg. Volume: 24,776
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.21
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

LakeShore Biopharma's overall stock score is significantly impacted by its poor financial performance, marked by declining revenue and substantial losses. The technical analysis indicates bearish momentum, though the stock is in oversold territory. Valuation remains uncertain due to the absence of key metrics, but the low market price may offer speculative value if financial conditions improve.

LakeShore Biopharma Business Overview & Revenue Model

Company Description

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.

How the Company Makes Money

LakeShore Biopharma generates revenue through a combination of product sales, licensing agreements, and strategic partnerships. Key revenue streams include sales of its proprietary therapeutics and diagnostic solutions to healthcare providers, hospitals, and research institutions. LSB also licenses its technology and compounds to other pharmaceutical companies, providing an additional source of income through upfront payments, milestone payments, and royalties. Strategic partnerships with academic institutions and industry leaders further bolster LSB's earnings by facilitating co-development projects and expanding market reach.

LakeShore Biopharma Financial Statement Overview

Summary

LakeShore Biopharma is facing financial challenges with declining revenues, substantial losses, and negative cash flows. The company's financial health is strained, requiring close attention to improve profitability and cash flow management.

Income Statement

LakeShore Biopharma has experienced declining revenue over the past year, with a notable decrease in total revenue from $687 million to $573 million, reflecting an annual revenue growth rate of -16.56%. The company also reports negative margins, with a net profit margin of -75.58% and an EBIT margin of -77.75% for the latest year, indicating significant losses relative to revenue. These factors highlight a challenging financial situation, with substantial operational losses.

Balance Sheet

The company's balance sheet reveals a debt-to-equity ratio of 0.73, which suggests moderate leverage but potentially higher risk given the industry's volatility. Stockholders' equity decreased from $728 million to $585 million, highlighting a decline in equity value. The equity ratio stands at 38.67%, indicating that a fair portion of the company's assets is financed through equity, but the decline in equity suggests potential instability.

Cash Flow

Cash flow analysis shows a negative free cash flow growth rate, with free cash flow deteriorating from -$239 million to -$339 million. The operating cash flow to net income ratio is negative, reflecting cash flow challenges in line with operational losses. These patterns point to liquidity concerns and the need for improved cash flow management to support operations.

Breakdown
Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
573.42M	687.20M	502.95M	257.02M
	Gross Profit
455.73M	533.84M	385.88M	197.36M
	EBIT
-445.83M	-139.38M	-549.18K	-125.85M
	EBITDA
-368.66M	-76.80M	-67.20M	-116.78M
	Net Income Common Stockholders
-433.46M	-145.48M	-545.73K	-191.83M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
246.35M	370.11M	885.20K	390.46M
	Total Assets
1.51B	1.72B	201.03M	91.37K
	Total Debt
424.46M	498.63M	380.59M	5.01K
	Net Debt
178.11M	128.52M	379.70M	-390.45M
	Total Liabilities
927.82M	991.30M	20.35M	70.01K
	Stockholders Equity
585.21M	728.45M	180.68M	21.36K
Cash Flow		Free Cash Flow
-339.48M	-239.52M	-299.55M	-351.49M
	Operating Cash Flow
-295.23M	-182.47M	-613.23K	-246.61M
	Investing Cash Flow
-44.25M	-56.98M	-200.00M	-104.24M
	Financing Cash Flow
205.26M	317.45M	201.50M	739.26M

LakeShore Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSB, the sentiment is Negative. The current price of 1.07 is below the 20-day moving average (MA) of 1.21, below the 50-day MA of 1.73, and below the 200-day MA of 3.13, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 26.66 is Positive, neither overbought nor oversold. The STOCH value of 16.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LSB.

LakeShore Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
NRXP	45 Neutral	$42.36M	―	108.28%	―	―	41.01%
CASI	41 Neutral	$30.07M	―	-1094.50%	―	11.40%	-18.18%
HOWL	40 Underperform	$49.81M	―	-82.81%	―	-92.95%	-50.02%
LSB	39 Underperform	$20.42M	―	-74.07%	―	―	―
ATRA	32 Underperform	$40.78M	―	1063.61%	―	475.53%	89.94%